New insights just presented at #NYValves2026 🗽🔥
Dive into the latest simultaneous publication in Structural Heart exploring real-world timing and patterns of sequential transcatheter valve interventions.
🔗 https://t.co/0o9kit29yS
#CardioX#CardioResearch@HarunKundi
Great results. One question: how exactly was reintervention defined? Did it include PVL closure, or was it limited to redo AVR only?
Also, the figure mentions KM estimates—was reintervention analyzed using competing risks (death) accounted for with a CIF approach? @rwyeh
Late-breaking real-world evidence at #CRT2026:
Linking registry + Medicare claims offers one of the clearest looks yet at long-term TAVR durability in low-risk patients.
Highlights:
��� 12,684 low-risk patients
• Reintervention remained low across generations
• ~2–3% at 5–6 years overall
• Mortality remained substantial, reflecting real-world aging/comorbidity burden
A valuable look at durability beyond trial populations.
Great work by @rwyeh and team!
#TAVR #StructuralHeart #CardioX @crt_meeting @ron_waksman @GreggWStone @TheDoctorMack @KarenMKimMD1 @PopmaJeffrey @MReardon19 @SachinGoelMD
Alanında en kapsamlı eser olan "Bilimsel Makale ve Yayıncılık " Kitabımız yayımlandı. Tüm meslektaşlarımıza faydalı olmasını dilerim.
https://t.co/rZxqOWRmpr
Grateful to contribute as faculty at #TCT2025 — discussing clinical trials, real-world evidence, AI-driven protocol design, and TAVR outcomes.
Proud to see how innovation, data, and collaboration are transforming cardiovascular research.
#cardiotwitter@crfheart@TCTMD
Our @crfheart new @JACCJournals analysis of 172,478 Medicare patients ≥65y shows in mitral valve interventions
Surgery ↓15.7%
M-TEER ↑95%
TMVR ↑100%
5-yr mortality: Surgery 39.5%, TMVR 55.1%, M-TEER 61.9%
Frailty and social vulnerability = key predictor of outcomes
@djc795@JACCJournals@crfheart@PopmaJeffrey Thank you so much, @djc795 — I truly appreciate your support.
Hopefully, future studies will further clarify whether less invasive approaches can mitigate this excess risk.
📢 Our new study is out in @JACCJournals
🔍 In patients aged 65 and older undergoing SAVR, nearly 50% undergo concomitant procedures, which are associated with increased short- and long-term mortality.
👉 https://t.co/A5R611yN4g
#TAVR@crfheart@djc795@PopmaJeffrey
🫀 Just wrapped up an incredible experience at #NYValves2025
Honored to have presented and participated as a discussant in several key
Grateful for the opportunity to contribute to discussions shaping the future of structural heart disease management.
@crfheart
We would like to invite you to contribute research articles, case reports
comprehensive reviews in the field of Interventional Cardiology to the journal Interventional Cardiology Perspectives.
https://t.co/k61VJZqadU
@intcarper@TGKDorg@HarunKundi#interventionalcardiology
Girişimsel Kardiyoloji Derneği'nin dergisi olan Interventonal Cardiology Perspectives dergimizin yayın hayatına başladığını duyurmaktan mutluluk duymaktayim. Dergimize makalelerinizi aşağıdaki linkten submit edebilirsiniz.
https://t.co/k61VJZqI3s
@TGKDorg@HarunKundi
Ready to Washington, DC for #TCT2024@TCTMD - excited for a deep dive into high-quality interventional cardiology science and to connect with brilliant colleagues
@crfheart
Our latest study in @JACCJournals reveals a link between obesity and psychological distress among young adults, with significant impacts on non-Hispanic White individuals and females. #CardioTwitter
👇
https://t.co/D1gE1CIlIn
Had a fantastic time at #NYValves2024 with the amazing @crfheart team! Great discussions, innovative ideas, and wonderful networking. Looking forward to #NYValves2025
#NYValves2024@crfheart
Featured research in AV Intervention
🔹French VALVENOR Registry: age/futility & patterns of SAVR/TAVR choice
🔹Great diversity in the panel that noted global differences in practice eg Korea TAVR reimbursement for >80 & Gulf mean age 72yr
🔹Futility poorly projected ~50%